Potent and Safe Immunotherapies for a Cancer-Free Future
Scancell is a clinical stage biotech company developing immunotherapies for a cancer-free future by enhancing long-lasting tumour specific immunity. With deep roots in cancer immunology and translational research, we aim to translate our innovation and creativity to address the need for fast, potent and accessible therapies that are easy to administer in hard-to-treat cancers.
Our Approach
Scancell is advancing a pipeline of safe, potent and highly effective immunotherapies to transform cancer treatment for millions of patients across multiple indications. Supported by a growing portfolio of off-the-shelf cancer therapy products, which provide rapid and scalable solutions, our advanced therapeutic vaccine programmes, SCOPE and ModiFY, have shown promising efficacy in Phase 2 trials, demonstrating long-term survival in metastatic melanoma and a broad range of solid tumours.
Meet our leadership team
Scancell has a bold ambition: to develop and deliver potent and safe immunotherapies for a cancer-free future. Our leadership team combines experienced and talented people who are committed to advancing our clinical programmes and translating innovative science for patient benefit.
LATEST NEWS
Scancell initiates new arm (Cohort 4) in SCOPE Phase 2 study to evaluate intradermal administration and an accelerated dosing regimen for iSCIB1+
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Q&A with Scancell CMO Nermeen Varawalla
Could you tell us a bit about your background and what attracted you to Scancell? Given my educational background, which includes an MD in clinical medicine, DPhil (Oxon) in molecular medicine and INSEAD MBA, along with extensive leadership and clinical development...
JOIN OUR MAILING LIST
Sign up for news updates to stay up to date with Scancell.